Combination therapy of an IL-15 superagonist complex, ALT-803, and a tumor targeting monoclonal antibody promotes direct antitumor activity and protective vaccinal effect in a syngenic mouse melanoma model

Gelijkaardige items

• A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses
  door: Liu, Bai, et al.
  Gepubliceerd in: (2016)
• Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models
  door: Liu, Bai, et al.
  Gepubliceerd in: (2018)
• The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8(+) T cells into innate-like effector cells with antitumor activity
  door: Wong, Hing C, et al.
  Gepubliceerd in: (2013)
• Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model
  door: Mathios, Dimitrios, et al.
  Gepubliceerd in: (2015)
• CITN-06: a Phase I/expansion trial of alt-803, an IL-15 superagonist, in patients with advanced melanoma
  door: Margolin, Kim, et al.
  Gepubliceerd in: (2014)